Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
16.66
+0.55 (3.41%)
At close: Jun 23, 2026, 4:00 PM EDT
16.36
-0.30 (-1.80%)
After-hours: Jun 23, 2026, 7:13 PM EDT
Amneal Pharmaceuticals Revenue
Amneal Pharmaceuticals had revenue of $722.52M in the quarter ending March 31, 2026, with 3.90% growth. This brings the company's revenue in the last twelve months to $3.05B, up 7.62% year-over-year. In the year 2025, Amneal Pharmaceuticals had annual revenue of $3.02B with 8.05% growth.
Revenue (ttm)
$3.05B
Revenue Growth
+7.62%
P/S Ratio
1.74
Revenue / Employee
$350,099
Employees
8,700
Market Cap
5.31B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.02B | 224.80M | 8.05% |
| Dec 31, 2024 | 2.79B | 400.35M | 16.73% |
| Dec 31, 2023 | 2.39B | 181.31M | 8.20% |
| Dec 31, 2022 | 2.21B | 118.63M | 5.67% |
| Dec 31, 2021 | 2.09B | 101.15M | 5.08% |
| Dec 31, 2020 | 1.99B | 366.15M | 22.51% |
| Dec 31, 2019 | 1.63B | -36.62M | -2.20% |
| Dec 31, 2018 | 1.66B | 629.34M | 60.89% |
| Dec 31, 2017 | 1.03B | 15.42M | 1.51% |
| Dec 31, 2016 | 1.02B | 151.95M | 17.54% |
| Dec 31, 2015 | 866.28M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Elanco Animal Health | 4.89B |
| Dr. Reddy's Laboratories | 3.58B |
| Hims & Hers Health | 2.37B |
| Alkermes | 1.56B |
| Lantheus Holdings | 1.55B |
| Prestige Consumer Healthcare | 1.09B |
| BioCryst Pharmaceuticals | 885.72M |
| Supernus Pharmaceuticals | 776.83M |
AMRX News
- 5 days ago - Amneal Pharmaceuticals Proxy statement: Proxy filing - Filings
- 6 days ago - The Healthcare M&A Wave - Forbes
- 13 days ago - Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals - PRNewsWire
- 14 days ago - Amneal Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 18 days ago - Amneal Pharmaceuticals announces interim results from ELEVATE-PD study - TheFly
- 18 days ago - Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease - GlobeNewsWire
- 19 days ago - Amneal Pharmaceuticals announces FDA approval of romidepsin injection solution - TheFly
- 19 days ago - Amneal Pharmaceuticals announces FDA approval of romidepsin injection solution - TheFly